PRTA PROTHENA CORP PUBLIC LTD CO
Pharmaceutical Preparations · Nasdaq · SEC CIK 1559053 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY347.4%
TTM net income YoY91.5%
TTM EPS YoY91.3%
Revenue 3-yr CAGR-27.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-64.6%
Net margin-45.4%
FCF margin—
EBITDA margin-63.1%
Returns
ROE-8.5%
ROA-7.5%
ROIC (approx.)—
Asset turnover0.17x
Leverage & solvency
Liabilities / assets5.2%
Debt / equity0.00x
Current ratio23.95x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.31x
Accruals ratio2.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $620,000 | $1.01M | $51.08M | $21,000 | $2.42M | $4.42M | $2.83M | $2.12M |
| R&D expense | $8.43M | $8.80M | $12.63M | $14.59M | $28.94M | $40.52M | $50.81M | $50.17M |
| SG&A expense | $10.59M | $10.90M | $12.67M | $12.65M | $13.24M | $15.91M | $17.60M | $16.85M |
| Operating income | -$18.82M | -$21.10M | $30.04M | -$24.20M | -$40.24M | -$84.62M | -$65.58M | -$64.90M |
| Pretax income | -$16.51M | -$18.58M | $32.72M | -$21.58M | -$36.91M | -$80.97M | -$61.37M | -$59.50M |
| Income tax | $2,000 | $2,000 | $1,000 | $10,000 | -$371,000 | $44.80M | -$1.18M | -$1.54M |
| Net income | -$16.51M | -$18.58M | $32.72M | -$21.59M | -$36.54M | -$125.77M | -$60.20M | -$57.96M |
| EBITDA | -$18.62M | -$20.90M | $30.22M | -$23.98M | -$40.04M | -$84.42M | -$65.36M | -$64.68M |
| EPS (basic) | -0.32 | -0.36 | 0.61 | — | -0.68 | -2.34 | -1.12 | — |
| EPS (diluted) | -0.32 | -0.36 | 0.60 | — | -0.68 | -2.34 | -1.12 | — |
| Weighted avg. shares (diluted) | 51.44M | 52.15M | 54.11M | — | 53.83M | 53.83M | 53.83M | — |
| Banking | ||||||||
| Net interest income | $2.32M | $2.55M | $2.42M | $2.65M | $3.35M | $3.79M | $4.35M | $5.39M |
| Balance sheet | ||||||||
| Cash & equivalents | $271.37M | $288.19M | $329.46M | $307.53M | $330.84M | $371.44M | $417.94M | $472.25M |
| Receivables | — | — | — | — | — | — | — | $0 |
| Current assets | $273.86M | $292.01M | $339.20M | $315.19M | $339.97M | $385.48M | $436.17M | $485.41M |
| PP&E, net | $2.30M | $2.49M | $1.96M | $2.14M | $2.46M | $2.69M | $2.87M | $3.08M |
| Total assets | $283.52M | $302.58M | $349.89M | $326.80M | $352.63M | $399.07M | $495.34M | $547.11M |
| Current liabilities | $11.43M | $11.66M | $32.52M | $40.84M | $51.44M | $67.81M | $48.46M | $48.50M |
| Total liabilities | $14.68M | $15.69M | $37.28M | $46.33M | $57.64M | $74.73M | $57.66M | $60.18M |
| Shareholders' equity | $268.84M | $286.89M | $312.62M | $280.47M | $294.99M | $324.33M | $437.68M | $486.93M |
| Shares outstanding | 51.34M | 51.74M | 53.08M | 53.83M | 53.83M | 53.83M | 53.83M | 53.83M |
| Cash flow statement | ||||||||
| Operating cash flow | -$11.96M | -$25.05M | $28.88M | -$23.31M | -$40.56M | -$46.34M | -$53.36M | -$47.77M |
| Investing cash flow | -$73,000 | -$652,000 | $0 | $0 | -$10,000 | -$86,000 | -$42,000 | -$43,000 |
| Financing cash flow | -$4.79M | -$15.57M | -$6.95M | $0 | -$17,000 | -$74,000 | -$48,000 | -$59,000 |
| Depreciation & amortization | $200,000 | $200,000 | $184,000 | $218,000 | $200,000 | $200,000 | $223,000 | $221,000 |
| Stock-based compensation | $6.41M | $7.88M | $6.92M | $7.07M | $7.20M | $12.42M | $10.95M | $10.52M |
Free plan shows the latest 8 periods; Pro shows all 59 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.